secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044756
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M
-------------------------------------------------------------------------------

- Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).
- Net loss $5.0M vs net income $9.2M in Q3 2023, which included $11M bargain purchase gain.
- Adjusted EBITDA loss $196K vs $440K gain; gross margin 58.4% down from 61.3%.
- Reaffirmed FY2024 revenue guidance $116-120M, representing 27-31% annual growth.
- Launched OsteoVive+ and Cortera system; signed license agreement for minimum $5.25M in fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/0001493152-24-044756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315224044756/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer